|Bid||0.0000 x 2200|
|Ask||0.0000 x 900|
|Day's range||3.3200 - 3.5500|
|52-week range||1.6000 - 14.7100|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||14.00|
TScan Therapeutics, Inc. ( NASDAQ:TCRX ) just released its second-quarter report and things are looking bullish...
TScan Therapeutics, Inc. ( NASDAQ:TCRX ) shareholders will have a reason to smile today, with the analysts making...
Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings anticipated by year-end 2022 Appointment of Debora Barton, M.D., as Chief Medical Officer Ended quarter with cash and cash equivalents of $125.6 million, funding operations into 2024 WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics,